Article Data

  • Views 773
  • Dowloads 130

Editorials

Open Access

Potential biomarkers associated with malignancy in uterine mesenchymal tumors

  • Takuma Hayashi1,2,*,
  • Nobuo Yaegashi3
  • Susumu Tonegawa4
  • Ikuo Konishi1,5

1Department of Cancer Medicine, National Hospital Organization Kyoto Medical Center, 612-8555 Kyoto, Japan

2Department of Industry Creation Program, START-prigram, Japan Science and Technology Agency (JST), 102-8666 Tokyo, Japan

3Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 980-8575 Miyagi, Japan

4Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

5Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 606-8303 Kyoto, Japan

DOI: 10.31083/j.ejgo4205125 Vol.42,Issue 5,October 2021 pp.824-828

Submitted: 18 June 2021 Accepted: 20 July 2021

Published: 15 October 2021

*Corresponding Author(s): Takuma Hayashi E-mail: yoyoyo224@hotmail.com

Cite and Share

Takuma Hayashi,Nobuo Yaegashi,Susumu Tonegawa,Ikuo Konishi. Potential biomarkers associated with malignancy in uterine mesenchymal tumors. European Journal of Gynaecological Oncology. 2021. 42(5);824-828.

References

[1] Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemi-ology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecologic Oncology. 2004; 93: 204–208.

[2] Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecologic Oncology. 2017; 145: 208–216.

[3] Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology. 2004; 67: 33–39.

[4] Akahira J, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, et al. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology. 2006; 71: 333–340.

[5] Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Research. 1997; 57: 5379–5385.

[6] Bell SW, Kempson RL, Hendrickson MR. Problematic Uterine Smooth Muscle Neoplasms. American Journal of Surgical Pathology. 1994; 18: 535–558.

[7] Hayashi T. Current status of chemotherapy for uterine sarcoma in Japan. JAMA Oncology. 2021; 7: 1–2.

[8] Hendrickson MR, Tavassoli FA, Kempson RL, McCluggage WG, Haller U, Kubik-Huch RA.  Mesenchymal tumours and related lesions. In Tavassoli FA, Devilee P (eds.) World Health Organization Classification of Tumours. Pathology & Genetics.  Tumours of the Breast and Female Genital Organs (pp. 233–244).  Lyon: IARC Press. 2003.

[9] Leath CA, Huh WK, Hyde J, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecologic Oncology. 2007; 105: 630–634.

[10] Riopel J, Plante M, Renaud M, Roy M, Têtu B. Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecologic Oncology. 2005; 96: 402–406.

[11] Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, et al. Hormonal therapy in uterine sarcomas. Cancer Medicine. 2019; 8: 1339–1349.

[12] Hayashi T, Kodama S, Faustman DL. LMP2 expression and proteasome activity in NOD mice. Nature Medicine. 2000; 6: 1065–1066.

[13] Hayashi T, Faustman DL. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Research. 2002; 62: 24–27.

[14] Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kasai M, Ichimura T, et al. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Scientific Reports. 2011; 1: 180.

[15] Hayashi T, Horiuchi A, Aburatani H, Ishiko O, Yaegashi N, Kanai Y, et al. Potential biomarker for human uterine leiomyosarcoma. Journal of Clinical Medicine Research. 2014; 6: 392–394.

[16] Hayashi T, Kawano M, Sano K, Ichimura T, Gur G, Yaish P, et al. A novel diagnostic biomarker for human uterine leiomyosarcoma: PSMB9/β1i. Chinese Clinical Oncology. 2017; 6: 22.

[17] Hayashi T, Horiuch A, Aburatani H, Yaegashi N, Tonegawa S, Konishi I. A potential diagnostic biomarker: Proteasome LMP2/b1i-differential expression in human uterus neoplasm. 2012. Available at: https://www.nature.com/articles/npre.2012. 7082.1 (Accessed: 2 April 2012).

[18] Watanabe K, Hayashi T, Katsumata M, Sano K, Abiko K, Konishi I. Development of Uterine Leiomyosarcoma during Follow-up after Caesarean Section in a Woman with Uterine Leiomyoma. Anticancer Research. 2021; 41: 3001–3010.

[19] Donnellan R, Chetty R. Cyclin E in human cancers. FASEB Journal. 1999; 13: 773–780.

[20] Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, et al. Cyclin E ablation in the mouse. Cell. 2003; 114: 431–443.

[21] Méndez J. Cell proliferation without cyclin E-CDK2. Cell. 2003; 114: 398–399.

[22] Hayashi T, Kawano M, Ichimura T, Ida K, Ando H, Zharhary D, et al. Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma. Anticancer Research. 2016; 36: 4997–5007.

[23] Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. New England Journal of Medicine. 2002; 347: 1566–1575.

[24] Matsuda M, Ichimura T, Kasai M, Murakami M, Kawamura N, Hayashi T, et al. Preoperative diagnosis of usual leiomyoma, atypical leiomyoma, and leiomyosarcoma. Sarcoma. 2014; 2014: 498682.

[25] Hayashi T, Sano K, Ichimura T, Kanai Y, Zharhary D, Aburatani H, et al. Characteristics of Leiomyosarcoma: Induction ofHematogenous Metastasis by Isolated Uterine Mesenchymal Tumor Stem-like Cells. Anticancer Research. 2020; 40: 1255–1265.

[26] Hayashi T, Kobayashi Y, Sano K, Horiuchi A, Konishi I. Patent: Detection of uterine leiomyosarcoma using LMP2. Application JP2007548042A events. 2019. Available at: https://upload.u min.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000044182 (Accessed: 4 December 2019).

[27] Hayashi T, Ichimura T, Yaegashi N, Shiozawa T, Konishi I. Expression of CAVEOLIN 1 in uterine mesenchymal tumors: no relationship between malignancy and CAVEOLIN 1 expression. Biochemical and Biophysical Research Communications. 2015; 463: 982–987.

[28] Hayashi T, Sano K, Ichimura T, Tonegawa S, Yaegashi N, Konishi I. Diagnostic biomarker candidates including NT5DC2 for humanuterine mesenchymal tumors. International Journal of Trend in Scientific Research and Development. 2021; 5: 604–606.

[29] Ravegnini G, Mariño-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, et al. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Modern Pathology. 2013; 26: 743–749.

[30] Smooth muscle tumor of uncertain malignant potential of the uterine corpus. Female Genital Tumours WHO Classification of Tumours (pp. 279–280). 5th edn. WHO Classification of Tumours Editorial Board. World Health Organization. 2020.

[31] Hayashi T, Ichimura T, Kasai M, Sano K, Zharhary D, Shiozawa T, et al. Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination. Anticancer Research. 2017; 37: 1765–1772.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top